CellSearch circulating tumor cell (CTC) kit (Janssen Diagnostics LLC) for monitoring metastatic breast cancer
Record ID 32015000340
English
Authors' recommendations:
In 2014, an estimated 232,670 women will be diagnosed with breast cancer in the United States leading to approximately 40,000 deaths. Most deaths are due to metastatic disease, which is treated with palliative intent using surgery, radiation therapy, and/or chemotherapy. Pharmaceutical options are based on the histological and molecular characteristics of the primary tumor, have toxic side effects, and frequently are ineffective. Current methods for evaluating response to treatment and detecting disease progression include physical examination and serum tumor markers, which are largely unreliable, and imaging, which typically are not undertaken for several weeks after starting a new line of therapy. Moreover, none of these methods is reliable in predicting treatment response or the likelihood of disease progression or death, and patients may undergo toxic but ineffective treatment. One reason for the inability to reliably predict treatment response and health outcome is that molecular characteristics in metastases often differ from those in the primary tumor.
Molecular tumor characteristics typically are determined by biopsy, which is a significant source of morbidity and frequently is not possible in metastases. However, tumor cells can detach from primary and metastatic tumors and disseminate into circulating blood. Circulating tumor cells (CTCs) are rare in individuals without malignancy but are present at a wide range of frequencies in patients with metastatic cancer. Analysis of CTCs in peripheral blood has been proposed as a noninvasive real-time method to monitor tumor burden and molecular tumor characteristics, monitor and predict treatment response, and predict disease progression and death in patients with metastatic breast cancer.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=5666
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Neoplastic Cells, Circulating
- Predictive Value of Tests
- Clinical Laboratory Techniques
- Prognosis
- Biomarkers, Tumor
- Diagnostic Techniques and Procedures
- Neoplasm Metastasis
- Female
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.